CXBS (Corix Bioscience) LT-Debt-to-Total-Asset: 0.00 (As of Sep. 2017)


What is Corix Bioscience LT-Debt-to-Total-Asset?

Corix Bioscience CXBS -99.00% LT-Debt-to-Total-Asset is 0.00 as of Sep. 2017.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Corix Bioscience's long-term debt to total assests ratio for the quarter that ended in Sep. 2017 was 0.00.

Corix Bioscience's long-term debt to total assets ratio declined from Sep. 2016 (0.44) to Sep. 2017 (0.00). It may suggest that Corix Bioscience is progressively becoming less dependent on debt to grow their business.

Corix Bioscience  (OTCPK:CXBS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Corix Bioscience LT-Debt-to-Total-Asset Related Terms

Corix Bioscience LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Corix Bioscience's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience LT-Debt-to-Total-Asset Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.45

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.45 0.00 0.00 0.00

Corix Bioscience LT-Debt-to-Total-Asset Calculation

Corix Bioscience's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as

LT Debt to Total Assets (A: Dec. 2016 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2016 )/Total Assets (A: Dec. 2016 )
=5.077/11.37
=0.45

Corix Bioscience's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2017 is calculated as

LT Debt to Total Assets (Q: Sep. 2017 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2017 )/Total Assets (Q: Sep. 2017 )
=0/4.344
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Corix Bioscience (CXBS) has a LT-Debt-to-Total-Asset of 0.00 as of Sep. 2017. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Corix Bioscience and its competitors.
Is Corix Bioscience's LT-Debt-to-Total-Asset too high?
Corix Bioscience's current LT-Debt-to-Total-Asset is 0.00.
How does Corix Bioscience's LT-Debt-to-Total-Asset compare to BKIT and YBAO?
Corix Bioscience's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Corix Bioscience and its competitors. Corix Bioscience's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current LT-Debt-to-Total-Asset is 0.00 as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corix Bioscience Business Description

Address 18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.